Clinical Trials Logo

KRAS G12D clinical trials

View clinical trials related to KRAS G12D.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06218914 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Start date: February 5, 2024
Phase: Phase 1
Study type: Interventional

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.

NCT ID: NCT05786924 Recruiting - Colorectal Cancer Clinical Trials

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Start date: April 18, 2023
Phase: Phase 1
Study type: Interventional

BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanoma harboring BRAF or NRAS mutations, histiocytic neoplasms harboring BRAF or NRAS mutations, and other solid tumors harboring BRAF mutations. The study population for the Dose Expansion part of the study comprises adults with recurrent advanced/metastatic NSCLC harboring KRAS non-G12C mutations. All patients will self-administer BDTX-4933 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT05726864 Recruiting - Colorectal Cancer Clinical Trials

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

AMPLIFY-7P
Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

NCT ID: NCT05631899 Recruiting - Solid Tumor, Adult Clinical Trials

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with KRAS mutant peptide (KRAS-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of KRAS-EphA-2-CAR-DC vaccine; detect T cell response against KRAS mutant peptide and tumor neoepitopes after the treatment with KRAS-EphA-2-CAR-DC vaccine and ICIs.

NCT ID: NCT03647098 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer

KILLER
Start date: August 1, 2018
Phase:
Study type: Observational

This study aims to analyze the survival condition of different groups about non-small cell lung cancer patients with KRAS mutations. These groups are made according to the treatment regime, brain metastases and KRAS alterations.